

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

			W. L. & St. L. S. W.		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR .	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/500,972	07/02/2004	Melissa Egbertson	21021YP	1833	
210 MERCK AND	7590 05/15/2007		EXAM	EXAMINER	
P O BOX 2000)	,	CHUNG, SUS	CHUNG, SUSANNAH LEE	
RAHWAY, NJ	07065-0907		ART UNIT	PAPER NUMBER	
			1626		
•	•	•	MAIL DATE	DELIVERY MODE	
			05/15/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

_	ı
	и
•	۲ı

	Application No.	Applicant(s)				
	10/500,972	EGBERTSON ET AL.				
Office Action Summary	Examiner	Art Unit				
	Susannah Chung	1626				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONED	l. ely filed the mailing date of this communication. O (35 U.S.C. § 133).				
Status	·					
1) Responsive to communication(s) filed on 08 Ap	<u>oril 2007</u> .					
2a)⊠ This action is FINAL . 2b)☐ This	☑ This action is FINAL. 2b) ☐ This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under <i>E</i>	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.				
Disposition of Claims						
4) Claim(s) 1-20 is/are pending in the application.	4)⊠ Claim(s) <u>1-20</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) <u>1-18</u> is/are allowed.						
6) Claim(s) 19 and 20 is/are rejected.						
7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or	r election requirement					
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.	·				
10) The drawing(s) filed on is/are: a) acce	epted or b) objected to by the E	Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action of form P1O-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary Paper No(s)/Mail Da					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	5) D Notice of Informal P					
Paper No(s)/Mail Date <u>4/9/07</u> .	6) 🔲 Other:					

Application/Control Number: 10/500,972

Art Unit: 1626

DETAILED ACTION

Claims 1-20 are pending in the instant application. Claims 21-23 are canceled.

Response to Non-Final Office Action

Acknowledgment is made of applicant's response and amendment of the claims filed on 4/9/2007.

35 USC 103

Claims 1-13 and 18 were rejected under 35 U.S.C. 103(a) as being obvious over Yamada et al., U.S. Pat. Nos. 4,125,611 (`611 Patent) and 4,226,863 (`863 Patent). In view of the amendment to the claims and arguments the rejection has been obviated.

35 USC 112, 1st Paragraph Rejection

Claims 19 and 20 were rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement because the specification is not enabled to inhibit, treat, or delay HIV integrase or AIDS.

Applicants assert that assay data is sufficient (Response, page 31, lines 13 and 14). While assay data is compelling it does provide sufficient support for the use of the instantly claimed compounds in "inhibiting" and "treating" HIV integrase or of "delaying" the onset of AIDS in a subject in need thereof. Applicants point to a sufficient correlation between the HIV replication inhibition assay in Example 30 and in vivo efficacy of exemplary compounds such as CRIXIVAN and SUSTIVA. The chemical formula of CRIXIVAN is

Application/Control Number: 10/500,972

Art Unit: 1626

and the chemical formula of SUSTIVA is

Neither compounds are similar to the instantly claimed compounds

of formula,

Therefore, in vivo data for

CRIXIVAN or SUSTIVA cannot be used to show the in vivo efficacy of the instantly claimed compounds. Therefore, Claims 19 and 20 remain rejected under 35 USC 112, 1st paragraph for enablement issues.

Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

Art Unit: 1626

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susannah Chung whose telephone number is (571) 272-6098.

The examiner can normally be reached on M-F, 8am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Susannah Chung Patent Examiner, AU 1626 KAMAL A. SAEED, PH.D. PRIMARY EXAMINER

Joseph K. M[©]Kane

Supervisory Patent Examiner Art Unit 1626, Group 1620

Technology Center 1600

Date: 10 May 2006